NEW YORK, NY / ACCESSWIRE / April 27, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
VRT Shareholders Click Here: https://www.zlk.com/pslra-1/vertiv-holdings-co-loss-submission-form?prid=26451&wire=1
AUPH Shareholders Click Here: https://www.zlk.com/pslra-1/aurinia-pharmaceuticals-inc-information-loss-submission-form?prid=26451&wire=1
LILM Shareholders Click Here: https://www.zlk.com/pslra-1/lilium-n-v-f-k-a-qell-acquisition-corp-loss-submission-form?prid=26451&wire=1
* ADDITIONAL INFORMATION BELOW *
Vertiv Holdings Co (NYSE:VRT)
VRT Lawsuit on behalf of: investors who purchased April 28, 2021 - February 23, 2022
Lead Plaintiff Deadline : May 23, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/vertiv-holdings-co-loss-submission-form?prid=26451&wire=1
According to the filed complaint, during the class period, Vertiv Holdings Co made materially false and/or misleading statements and/or failed to disclose that: (1) the Company could not adequately respond to supply chain issues and inflation by increasing its prices; (2) as a result of the increasing costs, Vertiv's earnings would be adversely impacted; and (3) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)
AUPH Lawsuit on behalf of: investors who purchased May 7, 2021 - February 25, 2022
Lead Plaintiff Deadline : June 14, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/aurinia-pharmaceuticals-inc-information-loss-submission-form?prid=26451&wire=1
According to the filed complaint, during the class period, Aurinia Pharmaceuticals Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Aurinia was experiencing declining revenues; (ii) Aurinia's 2022 sales outlook for the Company's only product which it offers for the treatment of adult patients with active lupus nephritis, LUPKYNIS, would fall well short of expectations; (iii) accordingly, the Company had significantly overstated LUPKYNIS's commercial prospects; (iv) as a result, the Company had overstated its financial position and/or prospects for 2022; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
Lilium N.V. f/k/a Qell Acquisition Corp. (NASDAQ:LILM)
LILM Lawsuit on behalf of: investors who purchased March 30, 2021 - March 14, 2022
Lead Plaintiff Deadline : June 17, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/lilium-n-v-f-k-a-qell-acquisition-corp-loss-submission-form?prid=26451&wire=1
According to the filed complaint, during the class period, Lilium N.V. f/k/a Qell Acquisition Corp. made materially false and/or misleading statements and/or failed to disclose that: (1) Lilium materially overstates the design and capabilities of the Lilium Jet, an electric vertical take-off-and-landing aircraft for use in a new type of high-speed air transport system for people and goods; (2) Lilium materially overstates the likelihood for the Lilium Jet's timely certification; (3) Lilium misrepresents its ability to obtain or create the necessary batteries for the Lilium Jet; (4) the special purpose acquisition company merger would not and did not generate enough cash to commercially launch the Lilium Jet; (5) Qell Acquisition Corp. did not engage in proper due diligence regarding its merger with Lilium GmbH; and (6) as a result, Defendants' public statements and statements to journalists were materially false and/or misleading at all relevant times.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP